PIK3CA and melanoma: For the AKT inhibitor GSK690693, PIK3CA aberrations predicted resistance only in colon cancer cell lines, and PTEN mutations predicted resistance in CNS and melanoma cell lines but there were no associations when they occurred in other lineages (Table S12 in File S3).